EDP Biotech is focused on validating ColoPlex™ via six clinical research studies and launching the new product in Europe in 2023, then expanding to new markets in the US, Asia, and adding new clinical indications.
Utilizing a multiplex platform, EDP Biotech builds its pipeline of new in vitro diagnostic products for the early detection of other solid tumors and cancers.
